Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.43 |
| ▸ | F11 | P03951 | 6/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405518 | 1.00 | ALDH1A1 (0.51) | ALDH1A1TSHRKMT2ALMNAKDM4E | |
| SCHEMBL19668371 | 0.88 | KMT2A (0.44) | ALDH1A1TSHRKMT2ALMNAKDM4E | |
| SCHEMBL17221299 | 0.88 | ALDH1A1 (0.55) | ALDH1A1TSHRKMT2ALMNAKDM4E | |
| SCHEMBL30665150 | 0.88 | ALDH1A1 (0.52) | ALDH1A1TSHRKMT2ALMNAKDM4E | |
| SCHEMBL17232505 | 0.88 | ALDH1A1 (0.52) | ALDH1A1TSHRKMT2ALMNAKDM4E | |
| SCHEMBL29697621 | 0.88 | ALDH1A1 (0.55) | ALDH1A1TSHRKMT2ALMNAKDM4E | |
| SCHEMBL17221253 | 0.86 | ALDH1A1 (0.51) | ALDH1A1TSHRKMT2ALMNAKDM4E | |
| SCHEMBL21355200 | 0.86 | ALDH1A1 (0.51) | ALDH1A1TSHRKMT2ALMNAKDM4E | |
| Hydrochloric Acid SCHEMBL21354812 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TSHRKMT2ALMNAKDM4E | |
| SCHEMBL29792688 | 0.86 | ALDH1A1 (0.51) | ALDH1A1TSHRKMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| CN-114206852-A | Plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20220002275-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-06 | — | — | US | disclosed |
| US-11180484-B2 | Pyrazole derivatives as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| CN-113387933-A | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-109311847-B | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-07-06 | — | — | CN | disclosed |
| WO-2021028649-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028645-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| EP-3760622-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2021-01-06 | — | — | EP | disclosed |
| EP-3464271-B1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | ALDH1A1 1622/4885TSHR 1726/4885KMT2A 1556/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | ALDH1A1 1622/4885TSHR 1726/4885KMT2A 1556/4885 |
| US-11180484-B2 | Pyrazole derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 2328/4885TSHR 1525/4885KMT2A 2351/4885 |
| US-20220002275-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | ALDH1A1 2317/4885TSHR 1981/4885KMT2A 1538/4885 |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 2328/4885TSHR 1525/4885KMT2A 2351/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | ALDH1A1 1622/4885TSHR 1726/4885KMT2A 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.